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Graft-versus-host disease (GVHD) is a serious complication of allogeneic hematopoietic 
cell transplantation (HCT) and this occurs as donor T lymphocytes, activated by recipient 
antigen presenting cells (APC), attack the host tissues or organs. This APC activation is 
a crucial initial step of influencing the outcome of GVHD and is mediated by innate im-
mune signaling. Toll-like receptors (TLRs) and nucleotide binding oligomerization domain 
(NOD)-like receptors (NLRs) are important components of innate immunity; both fami-
lies of receptors are known for sensing various microbial ligands or danger signals. 
Signaling through TLRs/NLRs regulate activities of APCs, through phagocytosis, cytokine 
and chemokine release, delivery of APCs from peripheral tissues to draining lymph nodes, 
and antigen presentation. Several TLRs/NLRs have been identified and their ligands and 
signaling pathways have been described. Recent findings suggest a significant association 
of TLR/NLR polymorphisms with the increased risk for severe GVHD. Therefore, these 
TLR/NLR pathways likely contributing to immune response for GVHD may serve as novel 
therapeutic targets to facilitate allograft tolerance. This review summarizes the role of 
TLRs/NLRs innate immune receptors and signaling in GVHD pathophysiology.
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INTRODUCTION
  Graft-versus-host disease (GVHD) is a leading cause of 
mortality and morbidity following allogeneic hematopoietic 
cell transplantation (HCT). It i s  c a u s e d  b y  m a t u r e  d o n o r  
T lymphocytes, which recognize the tissues of the recipient 
as foreign, causing a severe inflammatory disease most often 
characterized by rash, diarrhea, and liver disease. GVHD 
is classified into acute or chronic forms by its symptoms, 
the amount of damage it has caused to the liver, skin and 
mucosa and gastrointestinal tract as well as its timing. While 
acute GVHD usually refers to disease presenting within the 
first 100 days post-transplant, chronic GVHD symptoms may 
occasionally present as early as 50-60 days post-transplant 
and symptoms may overlap, typified by broader tissue dam-
ages often involving connective tissues and exocrine glands. 
　GVHD is particularly virulent when there is a mismatch 
of major histocompatibility complex (MHC) class I or MHC 
class II antigen between the donor and the host. MHC mole-
cules are highly polymorphic glycoproteins that present pep-
tide antigens to T cells. While MHC class I molecules present 
peptides generated in the cytosol to CD8 T cells, MHC class 
II molecules present peptides degraded in the intracellular 
vesicles to CD4 T cells. Thus, it is commonly recommended 
that HCT be undertaken, when there is a human leukocyte 
antigen (HLA) (MHC of human) match between the donor 
and the host. However, GVHD can also occur in the context 
of disparities between minor histocompatibility antigens, 
which are peptides of polymorphic cellular proteins bound 
to MHC molecules that can lead to graft rejection when 
they are recognized by T cells. One set of proteins that 
induce minor histocompatibility responses is encoded on 
the male-specific Y chromosome and the responses induced 
by these proteins are called H-Y. Female anti-male minor 
histocompatibility response can occur in female transplant 
recipients, since Y chromosome-specific genes are not ex-
pressed in females. 
　Because GVHD is characterized by tissue damage caused 
by T-cell mediated immune attack, immunosuppression is 
commonly used in the setting of HCT. The use of im-
munosuppressive agents is to reduce the severity of GVHD 
with the potential to induce donor-specific tolerance and 
avoid increased risk of infection and cancer in transplant 
recipient. Donor T cell activation requires two signaling 
events including binding of the T-cell receptor (TCR) to Korean J Hematol 2011;46:69-79.
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an allogeneic peptide presented by the host MHC as well 
as co-stimulatory signals delivered by antigen presenting 
cells (APCs). Co-stimulatory signals involve the interaction 
of CD28 on the T cell with CD80 or CD86 on the APCs. 
CD28 activates a signal transduction pathway, acting through 
phosphoinositide 3-kinase (PI3K) to provide its co-stim-
ulatory signal for T cell activation. Dendritic cells or macro-
phages are major hematopoietic originated APCs and a ca-
pacity of these cells to activate antigen presentation is de-
termined by the innate immune mechanisms that sense vari-
ous types of microbial ligands or endogenous danger signals. 
With the discovery of Toll-like receptors (TLRs) and nucleo-
tide binding oligomerization domain (NOD)-like receptors 
(NLRs), the role of innate immunity in the regulation of 
adaptive immunity and modulation of immune tolerance 
has become an intense area of current investigation in the 
field of immunology. 
TLRs have been extensively studied for their ability to 
activate signaling pathways in response to microbial or viral 
infection and to provide a link between innate and adaptive 
immunity, as TLR signals augment antigen presentation by 
innate immune cells [1]. Following ligand recognition or 
cellular disruption, these receptors activate downstream sig-
naling pathways, such as nuclear factor kappa B (NF-κB), 
mitogen activated protein kinase (MAPK) and type I interfer-
on (IFN) pathways, which result in the up-regulation of 
pro-inflammatory cytokines and chemokines that are im-
portant in inflammatory and antimicrobial responses. In ad-
dition to TLRs, NLRs also function to recognize pathogens 
and form a multi-protein intracellular complex with cas-
pase-1, known as inflammasome, which lead to release of 
interleukin-1β  (IL-1β), interleukin-18 (IL-18) and inter-
leukin-33 (IL-33) [2].
　Exploration of the potential r o l e  o f  T L R s / N L R s  i n  t h e  
outcome of GVHD is in its early stages. In addition to their 
role in host defense against pathogenic microorganisms, 
TLRs/NLRs also sense endogenous ligands/danger signals [3] 
and this danger sensing may play a major role in survival 
and maintenance of the grafted organs [4]. Furthermore, 
studies of gastrointestinal GVHD show that the loss of in-
testinal homeostasis or tissue integrity contributed sig-
nificantly to increased systemic severity of GVHD and this 
could be mediated by TLR4 [5] or NOD2 [6]. Given that 
polymorphisms in TLRs/NLRs are associated with increased 
risk of severe GVHD, understanding the mechanisms by 
which TLRs/NLRs play a role in GVHD pathophysiology 
is essential. 
　Recent advances in our understanding of how innate im-
mune receptors recognize pathogen-associated molecular 
patterns (PAMPs) as well as danger-associated molecular 
patterns (DAMPs) and trigger adaptive immune response 
may provide a new insight into molecular mechanisms by 
which a specific modulation of these pathways can be used 
as novel therapeutic approaches for GVHD. We discuss our 
current knowledge of the biology of the TLRs/NLRs and 
the mechanisms of their pathogen recognition as well as 
non-pathogen recognition function. Furthermore, we focus 
on their potential role in pathophysiology of GVHD and 
discuss future therapeutic targets. 
INTRODUCTION TO TOLL-LIKE RECEPTORS (TLRs)
　Toll-like receptors (TLRs) are innate immune receptors 
capable of sensing various components of microbial organ-
isms, such as lipid, carbohydrates, peptides, and nucleic acid. 
As evolutionarily conserved molecules, TLRs were first de-
scribed in vertebrates as homologous proteins to insect mole-
cule, Toll that stimulates the secretion of antimicrobial pep-
tides in Drosophila Melagaster [7]. To date, 11 members 
of TLRs have been identified in human (13 TLRs in mouse) 
and their expression patterns are quite diverse in that they 
are expressed on both innate and adaptive immune cells 
[1]. While some TLRs are expressed extracellularly, ex-
pression of other TLRs (such as 3,7/8,9) are limited to endo-
cytic or intracellular compartments. Most TLRs have trans-
membrane domains, composed of N-terminal extracellular 
leucine-rich repeats (LRRs) that are responsible for recog-
nition of specific pathogen components, a membrane-span-
ning domain and a C-terminal cytoplasmic domain similar 
to the cytoplasmic region of the interleukin-1 (IL-1) receptor, 
known as the Toll/IL-1 receptor (TIR) domain, which is 
required for downstream signaling. TLRs (except for TLR3), 
as well as IL-1R and IL-18R family members utilize MyD88 
as an adaptor molecule for downstream signaling [1].
　TLRs recognize diverse microbial patterns and have broad 
specificity, detecting many related molecular structures. 
TLR2 can either dimerize with TLR1 or TLR6. While TLR2/6 
heterodimers recognize diacyl lipoproteins from Mycoplasma 
species [8], TLR1/2 heterodimers recognize triacyl lipopro-
teins from various bacteria, including B. burgdorferi [9]. 
TLR3, which is found in endosomal compartments, recog-
nizes double-stranded RNA (dsRNA) [10]. TLR4 mainly rec-
ognizes lipopolysaccharides (LPS) of gram-negative bacteria 
[11] and interacts with CD14 and MD2 [12, 13]. TLR5 specifi-
cally recognizes bacterial flagellin [14]. Both TLR7 and 8 
sense single-stranded RNA (ssRNA) [15], whereas TLR9 is 
responsible for the recognition of unmethylated CpG nucleo-
tides [16, 17]. TLR11 detects profilin and plays an important 
role in host defense against uropathogenic bacterial infection 
[18, 19].
　TLR signaling is generally divided into two pathways (Fig. 
1); MyD88-dependent and TRIF-dependent. Except for 
TLR3, TLRs utilize MyD88 as an adaptor molecule for signal-
ing, leading to NF-κB-dependent cytokine production. On 
the other hand, TLR3 (and TLR4) uses a MyD88-independent 
signaling pathway that involves the adaptor molecule called 
TIR-containing adaptor inducing IFN-β (TRIF), which can 
either promote the activation of NF-κB pathway or the in-
duction of type I interferon (IFN-α/β) [1]. Signaling pathways 
downstream of TLRs are shown in Fig. 1. In the case of 
MyD88-dependent signaling pathways, TIR domains of TLRs 
interact with MyD88 that recruits members of the IL-1R-as-
sociated kinase (IRAK) family. IRAK activation results in Korean J Hematol 2011;46:69-79.
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Fig. 1. Toll-like receptor (TLR) signaling pathway. Toll-like receptors (TLRs), except for TLR3, use a MyD88-dependent signaling pathway to induce 
NF-κB activation. TLR3, (and TLR4), on the other hand, can activate MyD88-independent, TRIF-dependent pathway to induce NF-κB or type I 
interferon (IFN) activation. MyD88 recruits TRAF6 and members of the IRAK family, leading to the activation of the TAK1 complex. The activated 
TAK1 complex then activates the IKK complex, consisting of IKKα, IKKβ and NEMO (IKK-γ), which catalyze the phosphorylation of IκB proteins. IκBs 
are degraded by the proteasome, allowing NF-κB to translocate into the nucleus. Simultaneously, the TAK1 complex activates the MAPK pathway, 
which results in the phosphorylation and activation of AP-1. NF-κB and AP-1 control inflammatory responses through the induction of inflammatory 
cytokines. The signaling cascade triggered by TLR3 uses MyD88-independent, TRIF-dependent pathway. TRIF recruits TRAF3, which then interacts 
with TBK1 and IKKi. These kinases mediate phosphorylation of IRF3. Phosphorylated IRF3 dimerizes and translocates into the nucleus to regulate 
transcription. TRIF also interacts with TRAF6 and RIP1, which mediate NF-κB activation. Activation of the IRF3, NF-κB and MAPK pathways results 
in the induction of type I IFN, particularly IFN-β. 
targeting downstream TNF receptor-associated factor 6 
(TRAF6), through the recruitment of transforming growth 
factor β activated kinase 1 (TAK1) and TAK1-binding protein 
2 (TAB2). These molecules ultimately lead to activation of 
the upstream kinases for mitogen-activated protein kinases 
(MAPK) and activation of NF-κB occurs, when IκB kinases 
(IKK) complex phosphorylates IκB, which leads to nuclear 
translocation of NF-κB. 
　Similar to MyD88-dependent pathway, TRIF-dependent 
pathway also activates NF-κB. In addition to NF-κB activa-
tion, the TRIF-dependent pathway can also lead to the in-
duction of type I interferon through phosphorylation and 
activation of the transcription factors, interferon regulatory 
factor 3 (IRF3) and IRF7 [20, 21]. TRIF is used by TLR3 
or TLR4 and can directly bind to TRAF6 via its TRAF6- 
binding motifs in the N-terminal region and TRAF6 then 
activates TAK1 in a manner similar to that in the MyD88-de-
pendent pathway [22, 23]. TRIF can also recruit a signaling 
complex involving the non-canonical IKKs, TBK1 and IKKi, 
which induce IRF3 activation, mediated by TRAF3 [24]. 
　A crucial role for TLRs in regulating the immune response 
is implicated in many cellular processes and diseases. Signa-
ling via TLRs can initiate inflammatory cascades in response 
to pathogens or cellular stress, and trigger the activation 
of adaptive immune responses by regulating expression of 
co-stimulatory molecules on APCs, such as CD40 or CD80/86, 
and thereby enhancing antigen presentation [25]. Recent 
findings indicate that TLRs are involved in the process of 
acute allograft rejection and that their activation can prevent 
transplantation tolerance. We will review the expression Korean J Hematol 2011;46:69-79.
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of TLRs and the impact of TLR signaling on grafted organs 
in studies using both animal experiments and human clinical 
genetic association results. We then discuss possible mecha-
nisms by which TLRs are involved in the rejection phenom-
enon and lead to increased alloimmune responses during 
GVHD.
THE ROLE OF TLRs IN GVHD
Efficient priming of adaptive immune response depends 
on antigen presentation and stimulation of co-stimulatory 
molecules. TLRs regulate the expression of these co-stim-
ulatory molecules and subsequently control the adaptive im-
mune response, thereby influencing T cell activities [25]. 
Thus, because of TLRs’ role in the control of adaptive immune 
response, it was hypothesized that TLR signals may influence 
the activation of donor T lymphocytes and thus exacerbate 
the outcome of GVHD. Moreover, TLRs have been shown 
to be involved in regulatory mechanisms for ischemia-re-
perfusion injury (IRI), which is a major cause of delayed 
allograft function in solid organ transplantation (SOT) and 
an important inducer of acute and chronic transplant re-
jection [26-30]. Evidences suggesting a role for TLRs in im-
mune tolerance against allograft in SOT is based on studies 
from both animal experiments using knockout mice and 
human genetic single nucleotide polymorphism (SNP) analy-
sis. 
　LPS is a TLR4 ligand and LPS-mediated TLR4 activation 
leads to pro-inflammatory cytokine release [1]. The finding 
that LPS signals could influence the outcome of GVHD facili-
tated the use of LPS antagonist at the time of transplantation 
to reduce the risk of GVHD [31]. The importance of TLR 
signaling in graft intolerance using animal transplantation 
model was confirmed when Goldstein et al. reported the 
tolerance of MyD88-deficient mice towards H-Y minor histo-
compatibility antigen-mismatched transplant, suggesting 
that the GVHD in H-Y minor histocompatibility antigen- 
mismatched transplant in mice is dependent on the presence 
of TLR signaling [32]. The authors further investigated 
whether the absence of acute allograft rejection from the 
MyD88-deficient recipients could be restored by the adoptive 
transfer of WT-activated spleen cells. WT cells could re-acti-
vate the alloimmune response, confirming that TLR signaling 
exacerbates the alloimmune tolerance. Thus, these results 
suggest that the defect in the MyD88-deficient recipients 
most likely arises in the initiation phase of the alloimmune 
response because there are reduced numbers of mature den-
dritic cells migrating into draining lymph nodes, resulting 
in MyD88-deficient mice’s inability to generate alloreactive 
T cells and thus cause the intolerance. Furthermore, con-
sistent with this study, even for MHC-mismatched SOT, 
TLR signaling was found to be important for dendritic cell 
function and TH1 cell response, which influence the outcome 
of transplantation [33].
　In addition to animal studies described above, the im-
plication that TLR signaling may influence the severity and 
incidence of acute GVHD is also shown by human genetic 
association studies [34, 35]. An association between TLR4 
mutation and increased risk for GVHD was observed for 
patients who received organ grafts from human leukocyte 
antigen (HLA)-matched donor siblings, and increased risk 
for gram-negative bacteremia as a result of TLR4 mutation 
was also reported in these patients [34]. However, these 
associations are not statistically significant in recipients of 
HLA-matched sibling marrow transplants, prophylactically 
treated for infections and GVHD, suggesting that TLR4 poly-
morphisms may not cause more severe GVHD. However, 
another study indicates that there is a significant influence 
of mutations in TLR4 on the incidence and severity of acute 
GVHD in patients who underwent allogenic transplantation 
[35]. Interestingly, specific single nucleotide polymorphisms 
(SNP) in the coding region of the TLR4 gene in both the 
patient or donor side were associated with an increased risk 
for severe GVHD and intestinal GVHD. Based on the possi-
bility that microbiota may contribute to GVHD outcome, 
the use of antibiotics during GVHD was evaluated and metro-
nidazole and ciprofloxacin to decontaminate the intestine 
were found to be helpful for reducing the incidence of severe 
acute GVHD [35]. It is possible that differential composition 
of the intestinal microbiota from the recipients of HCT possi-
bly contributes to the outcome of graft survival and 
maintenance. The finding that suggests a role for TLRs in 
the control of intestinal microbiota environment [36] could 
be also a contributing factor that influences the occurrence 
and severity of GVHD. 
　Besides TLR4, several other TLRs have been also impli-
cated to play a role in GVHD pathophysiology. As mentioned 
earlier, TLR7/8 are known to recognize single-stranded RNA 
and induce anti-viral response. The expression of TLR7/8 
is present on plasmacytoid dendritic cells (pDCs) [37], which 
function as major anti-viral APCs. Jasperson et al. show 
that pDCs are capable of antigen presentation in GVHD 
and express immunosuppressive enzyme, indoleamine 2,3- 
dioxygenase (IDO), that influences GVHD pathophysiology 
[38]. Interestingly, administration of TLR7/8 agonist induced 
IDO expression and reduced GVHD pathogenecity [39]. In 
addition, TLR9, a receptor that recognizes CpG DNA, was 
also shown to be involved in GVHD outcome. TLR9 ligation 
of recipient APCs by CpG DNA markedly accelerated GVHD 
lethality in a mouse transplantation model [40].
　What are the mechanisms by which these TLR signals 
affect the outcome of GVHD? One possibility is that TLR- 
mediated activation of recipient APCs may lead to maturation 
and migration of APCs, thereby indirectly causing the activa-
tion of donor T lymphocytes. T cell activation is likely to 
be triggered by stimulation of TLR pathway, thereby promot-
ing the maturation and migration of alloantigen-expressing 
DCs to draining lymphoid organs. Transplantation studies 
with MyD88-deficient or MyD88/TRIF-deficient mice sup-
ported the hypothesis that TLR function on APCs is im-
portant for T cell activity and GVHD outcome. Defective 
TLR signals from either MyD88-deficient or MyD88/TRIF- 
deficient mice led to prolonged graft survival and this was Korean J Hematol 2011;46:69-79.
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consistent with diminished migration of donor cells to drain-
ing lymph nodes and subsequently, with delayed infiltration 
of host T cells into the grafted tissue [32, 41]. 
　Although previous studies mentioned above focused on 
TLR-mediated stimulatory effect o n  A P C s  t h a t  i n d i r e c t l y  
affect T cell response, there are studies to suggest direct 
effects of TLRs on T cell functions. Given that the expression 
of TLRs is not limited to innate immune cells, but is extended 
in different T cell subsets, including conventional  αβ  T 
cells, regulatory T cells, and γδ T cells as well as natural 
killer T cells, we can speculate that TLRs may be significant 
for induction of effector and regulatory function of T cells 
[42]. Stimulation of TLR ligand with purified CD4 T cells 
can directly promote activated CD4 T cell survival, suggesting 
that TLRs on T cells can directly modulate adaptive immune 
response [43, 44]. Furthermore, TLRs can act as a co-stim-
ulatory receptor via T cell receptor (TCR) engagement and 
can enhance the priming or survival of alloreactive T cells 
[45]. Another evidence that TLR stimulation provides a signal 
for T cell activation comes from the study using the admin-
istration of the TLR9 agonist CpG or of the TLR2 ligand 
Pam3CSK4 at the time of skin graft transplantation. This 
co-administration resulted in increased production of inter-
feron (IFN)-γ by alloantigen-stimulated splenocytes and im-
paired intra-graft regulatory T cells (Treg) recruitment, sug-
gesting that innate immune signals prevented alloimmune 
tolerance against the graft [46]. 
In addition to TLRs’ indirect or direct role in activation 
of T lymphocytes, TLRs may also participate in the control 
of intestinal microbiota, thereby contributing to the GVHD 
pathophysiology. Intestinal microbiota and endotoxin were 
proposed to have a significant impact on the APC activation 
and this could be a crucial and initiating step in the induction 
of alloreactions [47-49]. Compared with mice who died from 
acute GVHD, grown under conventional conditions early 
after transplantation, germ-free mice were resistant to devel-
oping acute GVHD, suggesting that intestinal microbiota 
could determine the susceptibility for GVHD severity [50]. 
Recent findings suggest that there is a significant association 
of TLR-mediated control of microbiota and the outcome 
of GVHD [47]. The beneficial role of the diversity of the 
intestinal microbiota on the outcome of GVHD has been 
suggested by Gerbitz et al. in that alteration of the intestinal 
microbiota may play an important role in the initiation of 
acute GVHD and the use of probiotics can ameliorate the 
outcome of GVHD [49]. Understanding the mechanisms by 
which the interaction of TLR-mediated innate immune acti-
vation with intestinal microbiota may shape the outcome 
o f  G V H D  r e m a i n s  t o  b e  i n vestigated in the future.
In summary, both animal transplantation model and hu-
man clinical genetic studies show that TLR-mediated signal-
ing is likely to play an important role in the pathogenesis 
GVHD. TLRs induce antigen presentation, together with 
TLR-mediated expression of co-stimulatory molecules and 
inflammatory cytokines, and instruct development of antigen 
specific adaptive immunity, especially helper T cells. There-
fore, alloimmune T cell responses can be enhanced by micro-
bial and/or endogenous TLR ligands induced by IRI and 
tissue stress/injury at the time of transplantation. Elucidation 
of the factors controlling TLR-mediated events after trans-
plantation could ultimately lead to novel therapeutic strat-
egies that target TLR signals to reduce the severity of GVHD. 
INTRODUCTION TO NLRs
Together with TLRs, NLRs represent central platforms 
of innate immunity that link sensing of microbial pathogens 
and metabolic stress to the activation of pro-inflammatory 
cytokines, such as IL-1β, IL-18 and IL-33. NLR signaling 
results in the formation of large molecular scaffold complexes 
(called inflammasome) [51], which are intricately linked with 
inflammation/autoimmunity [52, 53] and crosstalk with 
TLR-mediated signaling events [54]. Mutations/polymor-
phisms in NLRs have been linked to auto-inflammatory or 
autoimmune diseases [52, 55] and thus this suggest that NLRs 
function beyond the recognition of pathogens and act as 
central components of immune system. Since the discovery 
of inflammasome [51], NLRs-related studies have been fo-
cused on identifying molecules that are components of in-
flammasome and understanding how these molecules recog-
nizes danger signals. Activation of caspase-1 through auto- 
proteolytic maturation is thought to be a mechanism by 
which the processing and secretion of IL-1β occurs [51], 
however, further studies are required to determine the rela-
tive contribution of each of inflammasome mechanisms to 
innate and adaptive immune responses in response to danger 
signals. 
　More than 20 members of NLR family have been identified 
in mammals so far [56], however, the ligands and functions 
of many of these receptors remain undefined. In addition 
to TLRs, NLRs function as intracellular sensors that recognize 
pathogen-associated molecular patterns (PAMPs) as well as 
danger-associated molecular patterns (DAMPs) including 
cellular stress, and tissue damage/injury. NLRs are charac-
terized by C-terminal leucine rich domain, an intermediate 
NOD domain and an N-terminal effector region, comprising 
a protein-protein interaction domain, such as the caspase 
activation recruitment domain (CARD), pyrin (PYD) or ba-
culovirus inhibitor of apoptosis repeat domain (BIR) domain. 
NLRs have been grouped into several subfamilies on the 
basis of the effector domains: NOD, NALPs, and IPAF/NAIPs. 
NODs and IPAF contain CARD effector domains, whereas 
NALPs and NAIPs contain pyrin (PYD) effector domains 
and three BIR domains, respectively [56]. 
　NOD1/2 were first NLRs to be identified and characterized. 
NOD2 was first described as a Crohn’s disease susceptibility 
gene [57, 58] and later, NOD1/2 have been shown to be 
important for anti-microbial host response against bacterial 
pathogens and they are known to recognize peptidoglycans 
(PGN), cell wall components of bacteria. NOD1 is a sensor 
for D-γ-glutamyl-meso-DAP dipeptide (iE-DAP), which is 
found in PGN of all Gram-negative and certain Gram-positive 
bacteria [59], whereas NOD2 recognizes the muramyl dipep-Korean J Hematol 2011;46:69-79.
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Fig. 2. NOD-like receptor (NLR) family and inflammasome. NOD1/2 sense peptidoglycan fragments (iE-DAP and MDP) respectively and activate 
signaling pathways via the serine/threonine RIP2 kinase through CARD-CARD homophilic interactions. Once activated, RIP2 mediates the 
ubiquitination of NEMO/IKKγ leading to the activation of NF-κB and the production of inflammatory cytokines. In addition to the NF-κB pathway, 
NOD2 stimulation induces the activation of MAPKs. Several NALPs, NALP1, NALP3, and IPAF, have been identified to sense various ligands and form
a cytoplasmic mutiprotein complex called inflammasome. These NALPs recruit the adaptor protein ASC through their PYD domain, which in turn 
interacts with caspase-1 via a CARD-CARD interaction to form inflammasome. Consequently, inflammasome activation triggers the processing of
pro-caspase-1 into a mature form, caspase-1 and active caspase-1 induces cell death and the processing of pro-inflammatory cytokine pro-IL-1β 
into IL-1β. 
tide (MDP) [60]. Loss of NOD1 caused increased suscepti-
bility to Helicobacter pylori [61], while NOD2 deficient mice 
were more susceptible to Listeria monocytogenes infection 
[62, 63]. NOD2 is also regarded as a pivotal sensor molecule 
of the intestinal barrier, contributing to maintenance of in-
testinal homeostasis [64]. Once activated, NOD1 and NOD2 
oligomerize and recruit the NF-κB activating kinase RIP2 
through homotypic CARD-CARD interactions involving 
their N-terminal CARD motifs. RIP2 interacts with the regu-
latory NF-κB subunit, NEMO/ IKK-γ, triggering IκB phos-
phorylation and NF-κB activation [62, 65] (Fig. 2). 
NALPs (NLRPs) are characterized by the presence of PYD 
effector domains and so far, include 14 members. The func-
tion of many NLRPs still remains unknown, however, several 
NALPs (NLRP1, NLRP3, and NLRC4) have been shown to 
participate in the formation of inflammasome. NALP1 
(NLRP1) was shown to form cytoplasmic multicomplex with 
the adaptor called, apoptosis-associated speck-like protein 
containing a caspase recruitment PYCARD (ASC) and acti-
vate caspase-5. NLRP1 can be activated by two molecules, 
muramyl dipeptide (MDP) and the anthrax toxin [66, 67]. 
NALP3 (NLRP3) is the best studied NLR member, which 
has been shown to mediate caspase-1 activation in response 
to a variety source of stimulus; bacterial components [68-74], 
endogenous danger signals released by damaged cells or tis-
sues [75-77], and pore-forming toxins [78]. NLRP3 also inter-
acts with ASC to activate caspase-1 and NLRP3 signaling 
requires two stimulus, a cell priming signal from transcrip-
tionally active TLR, NLR, or cytokine receptor, prior to 
activation of NLRP3 with pore-forming toxins, ATP or vari-
ous endogenous danger signals. Similar to TLR5, IPAF 
(NLRC4) has been shown to respond to bacterial flagellin, 
a main component of the bacterial flagellum, restricting the 
proliferation of intracellular bacteria such as Salmonella ty-Korean J Hematol 2011;46:69-79.
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phimurium, Shigella flexneri, and Legionella pneumophila 
[79-82]. These bacteria use type III secretion system (TTSS) 
to secrete flagellin into cytoplasmic compartment where 
IPAF senses flagellin. NLRC4 lacks a PYD domain, and it 
could activate pro-caspase-1 directly, however, ASC is still 
required for full activation to induce the cleavage and secre-
tion of mature IL-1β [83].
Recent studies focused on highlighting the role of NLRs 
in broader control of adaptive immune response and various 
d i s e a s e  s t a t e s  [ 8 4 ] .  M a n y  N L R s  h a v e  b e e n  i d e n t i f i e d  a n d  
proposed to function as sensors for PAMPs as well as DAMPs, 
released through damaged mucosal barriers or skin. Specifi-
cally, DAMPs-stimulated NLR activation may participate in 
enhancing the severity of GVHD, similar to the role of TLRs, 
thus, it is important to understand potential contribution 
of NLRs to GVHD outcome. Below, we summarize the cur-
rent understanding of the function of NLRs in GVHD 
pathophysiology.
ROLE OF NLRs IN GVHD
Similar to TLRs, NLRs were also shown to mediate the 
immune response to IRI [85-87]. Therefore, NLRs were pro-
posed to influence the outcome of GVHD. Previous studies 
indicate an important role for NOD2 in contributing to sus-
ceptibility to GVHD after HCT [6, 35, 88-91] and mutations 
in NLRP2 and NLRP3 have been proposed to be prognostic 
markers for the clinical outcomes of allogenic transplantation 
[92]. In addition to the strong genetic association between 
NLR polymorphisms/mutations and GVHD susceptibilities 
by human SNP analysis, animal experiments using NOD2- 
deficient mice suggested a role of NOD2 in GVHD patho-
physiology. In contrast to TLRs, which drove donor T lym-
phocyte activation and severe GVHD outcome [32], the ab-
sence of NOD2 from the bone marrow transplant donor 
mice had no significant impact on the development of GVHD 
and did not regulate alloactivation of donor T cells. Instead, 
NOD2 deficiency in allo-bone marrow transplantation recip-
ients caused increased GVHD occurrence in both MHC-mis-
matched and MHC-matched models [93, 94]. Furthermore, 
the proliferation and activation of donor T cells were en-
hanced by the absence of NOD2 from all bone marrow trans-
plant recipients. This suggests that NOD2 plays a role in 
the regulation of host APCs, as evident by NOD2-deficient 
DCs displayed a higher activation status and increased ability 
to induce T cell proliferation during GVHD [93]. Several 
studies demonstrated a significant association between NOD2 
SNPs and increased GVHD incidence/severity [6, 35, 88-91]. 
In contrast to these studies, several clinical findings did not 
find a significant impact of NOD2 SNPs on the incidence 
of GVHD [95-98]. Multiple factors could explain the conflict-
ing results on the role of NOD2 and these may include 
differences in study population with NOD2 SNP frequency, 
overall incidence of GVHD, T cell activities, donor and recipi-
ent immune differences, and variation in environmental 
factors. Nonetheless, these data give new insight into the 
potential role of NOD2 in GVHD pathophysiology.
　Many cytokines have been identified to be risk factors 
for predicting the outcome and severity of GVHD [99]. IL-1β 
is one of key inflammatory cytokines involved in GVHD 
pathophysiology and increased production of IL-1β is found 
to be associated with worse outcomes of GVHD [100]. Given 
that IL-1β is a major pro-inflammatory cytokine released 
following the activation of inflammasome, a genetic associa-
tion study was conducted to evaluate whether mutations 
in NLRP genes are associated with GVHD pathogenecity. 
The genotypes of 133 patients undergoing HLA-identical 
sibling allogenic stem cell transplantation (allo-SCT) were 
analyzed and a strong association between common genetic 
variants in NLRP2 and NLRP3 genes and clinical outcome 
of HLA-identical allo-SCT was reported [92]. 
Despite increasing evidence, suggesting the importance 
of common variants in NOD2 or NLRP genes on the clinical 
outcome of GVHD, the mechanisms underlying these associ-
ations remain unidentified. Cellular damage or stress can 
ultimately lead to release of danger signals, which cause 
excessive immune-mediated tissue destruction, often found 
in acute GVHD. Adenosine-5-triphosphate (ATP) has been 
recognized as an endogenous danger signal during GVHD 
[4, 101, 102]. Extracellular ATP and its receptor P2X7R are 
expressed on several immune cell types and have been shown 
to be an important signal for activating NLRP3 inflammasome 
[78]. Increased concentration of ATP was reported during 
the development of GVHD and ATP-mediated stimulation 
of APCs led to increased expression of co-stimulatory mole-
cules, such as CD80 and CD86 and further activated a variety 
of pro-inflammatory signaling pathways leading to expansion 
of donor T cells but reduction of regulatory T cells [101]. 
This data gives a new insight into the mechanisms by which 
danger signals enhance GVHD. Overall, studies characteriz-
ing the role of endogeneous or exogenous danger signals 
as well as their innate immune receptors in GVHD may 
hopefully help to develop a potential therapeutic target to 
bring a better clinical outcome for patients undergoing SOT 
or HCT. 
CONCLUSION
　Innate immune receptors significantly contribute to the 
inflammatory processes that consequently lead to the recruit-
ment of alloactivated T cells as well as tissue damage in 
GVHD target organs. Fig. 3 describes how the development 
of GVHD could be influenced by innate immune response. 
The generation of adaptive immunity can be triggered by 
activation of TLR-mediated APCs engulfing microbial patho-
gens or sensing danger signals in the peripheral tissues. 
Subsequently, APCs migrate to the draining lymph nodes 
to present the processed peptides to naïve T cells in the 
context of MHC molecules. Thus, TLRs provide signals neces-
sary for this migration or could act directly on T cell function. 
Consequently, this could result in accelerating the develop-
ment of severe GVHD. Korean J Hematol 2011;46:69-79.
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Fig. 3. Potential role of TLRs/NLRs in GVHD. GVHD occurs as a result of donor T lymphocyte activation reacting to antigens presented by recipient APCs. 
Recipient APCs, such as dendritic cells and macrophages, recognize PAMPs and DAMPs via TLRs/NLRs. Microbial pathogens or danger signals can be 
engulfed by phagocyotsis/endocytosis or through unidentified mechanisms, activate TLRs/NLRs on APCs. The ligation of TLRs leads to the maturation 
of APCs at the inflammatory site and enhances expression of co-stimulatory molecules and pro-inflammatory cytokines. This leads to a consequent 
migration of APCs to the draining lymph nodes. There, the APCs present alloantigens to naïve T cells, resulting in T cell activation and expansion. 
Activated T cells migrate back to the allograft and carry out their effector functions by attacking the graft. Thus, TLRs/NLRs-mediated antigen presentation 
may indirectly influence the alloreactivity of T cells or TLRs/NLRs may have a direct effect on T cells, thereby enhancing GVHD. 
　To date, most therapeutic and prophylactic efforts to pre-
vent GVHD have been relied on immunosuppression mecha-
nisms via T cell depletion or inhibition of T cell activation, 
proliferation, or effector function. Alternatively, immuno-
suppressive therapeutic strategies targeting key innate im-
mune receptor signaling pathways may also decrease the 
severity and incidence of GVHD. Anti-IL-1β therapies have 
been successfully used in treating auto-inflammatory diseases 
[103] and the use of IL-1β antagonist to reduce the severity 
of GVHD has been investigated [104]. Further studies on 
the role of TLRs/NLRs control of subsequent adaptive im-
mune response will enhance our knowledge of the overall 
host response to transplant grafts and hopefully lead to the 
development of strategies to modify this response and to 
improve clinical outcomes of SOT or HCT. 
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